-transparent.png){kind=logo}
TPCK (N-alpha-p-tosyl-L-phenylalanine chloromethylketone), a potent inhibitor of chymotryptic-type serine proteases, was found to decrease IL2 synthesis in Jurkat T cells. Conversely, the tryptic-type protease inhibitor, TLCK (N-alpha-p-tosyl-lysine chloromethylketone), which structurally is very similar to TPCK, had no effect on IL2 synthesis. Prostaglandin synthesis, a process that is known to reduce IL2 production in T cells, was increased by TPCK but not by TLCK, suggesting that this process could be, at least in part, responsible for the inhibition of IL2 production. Our results imply that a chymotryptic-type serine protease plays an active role in the regulation of IL2 synthesis and thus in the whole process of T-lymphocyte activation.
P Auberger, and
M Didier, and
J Didier, and
C Aussel, and
M Fehlmann
August 1990,
Immunology,
P Auberger, and
M Didier, and
J Didier, and
C Aussel, and
M Fehlmann
February 1989,
Journal of immunology (Baltimore, Md. : 1950),
P Auberger, and
M Didier, and
J Didier, and
C Aussel, and
M Fehlmann
January 1998,
Immunopharmacology,
P Auberger, and
M Didier, and
J Didier, and
C Aussel, and
M Fehlmann
July 2006,
International immunopharmacology,
P Auberger, and
M Didier, and
J Didier, and
C Aussel, and
M Fehlmann
January 1990,
Immunopharmacology,
P Auberger, and
M Didier, and
J Didier, and
C Aussel, and
M Fehlmann
February 1992,
Cellular immunology,
P Auberger, and
M Didier, and
J Didier, and
C Aussel, and
M Fehlmann
January 2004,
Biomedical sciences instrumentation,
P Auberger, and
M Didier, and
J Didier, and
C Aussel, and
M Fehlmann
April 2014,
Journal of traditional and complementary medicine,
P Auberger, and
M Didier, and
J Didier, and
C Aussel, and
M Fehlmann
January 2015,
PloS one,
P Auberger, and
M Didier, and
J Didier, and
C Aussel, and
M Fehlmann
September 1999,
Journal of biochemistry,
